Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.58 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.55 |
| ▸ | TUBB | P07437 | 2/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.55 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.55 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.55 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.55 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14527493 | 0.86 | CYP1A2 (0.57) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL12545539 | 0.82 | GSK3B (0.40) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL65201 | 0.80 | CYP1A2 (0.66) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL65200 | 0.80 | CYP1A2 (0.66) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL79794 | 0.80 | CYP1A2 (0.63) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL79672 | 0.78 | CYP1A2 (0.71) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL30743907 | 0.78 | CYP1A2 (0.83) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL80221 | 0.78 | CYP1A2 (0.63) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL79900 | 0.78 | CYP1A2 (0.67) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL79624 | 0.78 | CYP1A2 (0.70) | CYP1A2CYP2C9CYP2C19RAF1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633393-B2 | Tubulin binding compounds and therapeutic use thereof | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20200237754-A1 | TUBULIN BINDING COMPOUNDS AND THERAPEUTIC USE THEREOF | BEYONDSPRING PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8247552-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247552-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8129527-B2 | cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers | NEREUS PHARMACUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129527-B2 | cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers | NEREUS PHARMACUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110245260-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245260-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-7919497-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7674903-B2 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674903-B2 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | BEYONDSPRING PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | BEYONDSPRING PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| EP-1529044-B1 | DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS INC (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007035841-A9 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS INC (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | BEYONDSPRING PHARMACEUTICALS, INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | BEYONDSPRING PHARMACEUTICALS, INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2007035841-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245260-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | MKI67, HPGDS, HCCS | CYP1A2 2042/4885CYP2C9 4257/4885CYP2C19 3184/4885 |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | MKI67, HPGDS, HCCS | CYP1A2 2042/4885CYP2C9 4257/4885CYP2C19 3184/4885 |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | HPGDS, DHPS, HCCS | CYP1A2 1594/4885CYP2C9 3869/4885CYP2C19 2655/4885 |
| US-11633393-B2 | Tubulin binding compounds and therapeutic use thereof | TUBB6, TUBB1, TUBB | CYP1A2 4665/4885CYP2C9 4752/4885CYP2C19 4805/4885 |
| US-20200237754-A1 | TUBULIN BINDING COMPOUNDS AND THERAPEUTIC USE THEREOF | TUBB6, TUBB1, TUBB | CYP1A2 4665/4885CYP2C9 4752/4885CYP2C19 4805/4885 |
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | MKI67, HPGDS, HCCS | CYP1A2 2042/4885CYP2C9 4257/4885CYP2C19 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.